208 completed, 28 terminated, 11 recruiting, 10 withdrawn. 94 Phase 3, 58 Phase 2, 44 Phase 1, 44 Phase 4, 25 Not applicable.
Follow Bausch Health Americas, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis High dose budesonide rectal foam, Low dose budesonide rectal foam, Matching placebo rectal foam - Ulcerative Colitis | Phase 4 | Not yet recruiting | Bausch Health Americas, Inc. | 100 | 2029-06-01 | 2026-10-06 |
| Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder bupropion hydrobromide, Placebo - Major Depressive Disorder | Phase 4 | Not yet recruiting | Bausch Health Americas, Inc. | 246 | 2027-07-01 | 2026-09-29 |
| This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC plecanatide, Placebo - Functional Constipation (FC) | Phase 2 | Recruiting | Bausch Health Americas, Inc. | 180 | 2026-08-18 | 2026-10-07 |
| Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%. - Acne Vulgaris | Phase 4 | Recruiting | Bausch Health Americas, Inc. | 100 | 2026-04-01 | 2026-07-29 |
| Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT) - Diarrhea, Gastroenteritis | Phase 4 | Recruiting | Bausch Health Americas, Inc. | 54 | 2026-02-11 | 2026-08-13 |
| Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH) Larsucosterol, Placebo - Hepatitis | Phase 3 | Recruiting | Bausch Health Americas, Inc. | 350 | 2026-01-29 | 2026-10-15 |
| A Prospective Controlled Study to Evaluate the Safety and Effectiveness of Thermage® FLX Radiofrequency Treatment Thermage FLX - Wrinkle, Lax Skin | Not applicable | Recruiting | Bausch Health Americas, Inc. | 164 | 2025-10-31 | 2026-08-26 |
| A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing Fraxel® FTX Laser System - Skin Resurfacing | Not applicable | Active not recruiting | Bausch Health Americas, Inc. | 49 | 2025-10-17 | 2026-08-28 |
| Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris clindamycin phosphate, adapalene and benzoyl peroxide - Acne Vulgaris | Completed | Bausch Health Americas, Inc. | 200 | 2025-10-02 | 2026-09-09 | |
| Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet Naltrexone/Bupropion, Placebo - Obesity; Drug, Obesity, Morbid | Phase 4 | Recruiting | Laval University | 108 | 2025-06-04 | 2025-08-08 |
| Brodalumab in the Treatment of Immune-Related Adverse Events Brodalumab, CT scan - Breast Cancer, Esophageal Cancer | Phase 1 | Recruiting | Brian Henick, MD | 11 | 2025-03-11 | 2026-05-13 |
| Rifaximin SSD in Dementia Trial Rifaximin SSD 40 mg IR tablet, Placebo - Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease | Phase 1 / Phase 2 | Recruiting | Jasmohan Bajaj | 20 | 2024-12-30 | 2026-04-03 |
| Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity Contrave, Placebo, Diet Program - Obesity, Weight Loss | Phase 4 | Recruiting | The Royal's Institute of Mental Health Research | 40 | 2024-07-04 | 2025-07-24 |
| Rifaximin for the Secondary Prevention of Recurrent Pouchitis Rifaximin 550 MG Oral Tablet [XIFAXAN] - Pouchitis | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 16 | 2024-07-01 | 2026-08-03 |
| Experience With Topical Acne Treatment clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel - Acne | Early Phase 1 | Active not recruiting | Wake Forest University Health Sciences | 72 | 2024-02-15 | 2025-12-24 |
| Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Low Dose Budesonide, High Dose Budesonide, Placebo - Ulcerative Colitis | Phase 4 | Recruiting | Bausch Health Americas, Inc. | 70 | 2023-09-29 | 2025-09-16 |
| Duobrii Treatment of Acne Keloidalis Nuchae (AKN) Duobrii, Placebo, Bryhali - Acne Keloidalis Nuchae, AKN | Phase 3 | Terminated | Icahn School of Medicine at Mount Sinai | 15 | 2022-10-26 | 2025-11-04 |
| Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis Rifaximin SSD, Placebo - Hepatic Encephalopathy | Phase 3 | Active not recruiting | Bausch Health Americas, Inc. | 466 | 2022-08-03 | 2025-09-10 |
| Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis Rifaximin SSD, Placebo - Hepatic Encephalopathy | Phase 3 | Active not recruiting | Bausch Health Americas, Inc. | 524 | 2022-04-07 | 2025-07-24 |
| Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease Low Dose Rifaximin ER, Low Dose Rifaximin DER, High Dose Rifaximin ER - Sickle Cell Disease | Phase 2 | Completed | Bausch Health Americas, Inc. | 44 | 2022-03-22 | 2024-09-19 |
Showing 20 of 277. Sign in to see all of them.
Acne Vulgaris (28) · Psoriasis (19) · Colitis, Ulcerative (18) · Constipation (15) · Diarrhea (13) · Inflammatory Bowel Diseases (11) · Hepatic Encephalopathy (10) · Opioid-Induced Constipation (9) · Irritable Bowel Syndrome (8) · Hepatitis C, Chronic (7) · Chronic Pain (6) · Hepatitis C (6) · Epilepsy (5) · Gastrointestinal Diseases (5) · Abdominal Pain (4)
Rifaximin (31) · methylnaltrexone (28) · brodalumab (14) · plecanatide (13) · Ribavirin (8) · Tretinoin (6) · ezogabine (6) · Budesonide (5) · Mesalamine (5) · halobetasol (5) · tazarotene (5) · Adapalene (4) · Tramadol (4) · crofelemer (4) · taribavirin (4)
United States (219) · Canada (47) · Australia (15) · France (14) · Poland (14) · Germany (13) · Hungary (11) · Mexico (11) · Belgium (10) · Italy (10) · Russia (10) · United Kingdom (10) · Spain (9) · South Korea (6) · Bulgaria (5)
Anya Loncaric (22) · Tage Ramakrishna, MD (19) · Jeff Cohn (15) · Lindsey Mathew (15) · Varsha Bhatt (9) · Ralph T. Doyle (8) · Enoch Bortey (5) · Binu J Alexander (4) · Binu J Alexander, MD (4) · Ana Rossi, MD (3) · David Lineberry (3) · John Lahey (3) · Phyllis Diener, MT, ASCP (3)
PMID 37467180, PMID 32207067, PMID 32660770, PMID 33788162, PMID 37332239, PMID 40377868, PMID 24697851, PMID 26563167, PMID 36922331, PMID 20159311, PMID 20684151, PMID 21208106, PMID 21460676, PMID 21471758, PMID 21889833, PMID 22512894, PMID 22617015, PMID 24815199, PMID 25644096, PMID 26422722, PMID 26861051, PMID 27416045, PMID 27573565, PMID 30328108, PMID 30471012, PMID 31951150, PMID 32886337, PMID 34606048, PMID 35086735, PMID 35750249, PMID 38724841, PMID 39264399, PMID 41214272, PMID 12243706, PMID 15897530, PMID 17043337, PMID 18509120, PMID 19278178, PMID 19855267, PMID 19925497, PMID 20335583, PMID 20412178, PMID 20677537, PMID 20721883, PMID 20849805, PMID 21420555, PMID 21429809, PMID 21647654, PMID 21657861, PMID 21810165
R03DK140415 (1), R21NS077858 (1)